In the company’s news today,
Advanced Life Sciences, Inc. announced submission of a new drug application (NDA) for its lead product, cethromycin, a unique once-a-day antibiotic for respiratory tract infections. The NDA submission is for cethromycin in mild-to-moderate community-acquired pneumonia (CAP). Community-acquired pneumonia is the sixth most common cause of death in the U.S., affecting 5.6 million Americans annually.
Penicillins and macrolides are currently the most common treatment for CAP, but increasing resistance has driven the need for new antibiotics. CEO Michael Flavin, Ph.D., said, “We look forward to advancing the cethromycin NDA through the FDA review process.” The NDA submission is based on a full clinical development and manufacturing program for cethromycin. More than 5,000 patients have been treated with cethromycin in 53 clinical trials to date.
In addition, Advanced Life Sciences and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), have signed a development and commercialization agreement for cethromycin in the Asia Pacific region, excluding Japan. Advanced Life Sciences will retain exclusive rights to cethromycin in the rest of the world, including North America and Europe.
In conjunction with the NDA submission, Advanced Life Sciences has received a commitment to increase availability under its loan facility with Leaders Bank from $4 million to $10 million. The company also plans to partner with other organizations to advance its earlier stage programs.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona is a free service that collects data from hundreds Small-Cap and Micro-Cap online Investment Newsletters into one Free Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their advertising efforts and now has over 500,000+ subscribers that receive The Daily Stock Newsletters.
To sign up for “The QualityStocks Daily Newsletter” please visit http://www.qualitystocks.net/
Please see disclaimer on QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
